RESUMO
BACKGROUND: Limited information exists about the correlation between clinical history and positive serum (SAT) and intradermal allergen test (IDAT) results in atopic dogs. OBJECTIVES: To evaluate the correlation between clinical history and SAT/IDAT results in atopic dogs. ANIMALS: Twenty-nine client-owned dogs with nonseasonal atopic dermatitis with or without seasonal exacerbation were enrolled. MATERIALS AND METHODS: IDAT, SAT (immunoglobulin (Ig)M antibody capture enzyme-linked immunosorbent assay [MacELISA] with bromelain CCD inhibitor) and clinical information collected in a questionnaire regarding seasonal variations in pruritus affecting the dogs were performed on the same day. Two independent investigators (Inv A and Inv B) recorded IDAT results. RESULTS: The kappa coefficients agreement for positive IDAT scores between Inv A and B was substantial. The agreement between IDAT and SAT results at different ELISA absorbance units (EAU) cut-offs (>79 and ≥300) was slight and fair for both investigators, respectively. A higher agreement was observed between IDAT and SAT (≥300 EAU) than between IDAT and SAT (>79 EAU) with the exception of mite and flea allergens. There was a statistically significant association between clinical history and positive IDAT results for seasonal allergens (Inv A and Inv B, p = 0.016). There was no significance between positive SAT results and clinical history. Five (IDAT) and 12 of 13 (SAT) atopic dogs without clinical seasonal exacerbation showed positive results for seasonal allergens. CONCLUSIONS AND CLINICAL RELEVANCE: The agreement between IDAT and SAT ≥300 EAU results was fair and the agreement between IDAT and SAT >79 EAU results was slight for all allergens. Only positive IDAT results significantly correlated with clinical history.
RESUMO
BACKGROUND: Intravenous administration of interleukin (IL)-31 in healthy dogs has been used as a model to assess antipruritic drugs. However, there is no known in-depth characterisation of pruritic behaviours, and the repeatability of the IL-31-induced pruritus in the individual dogs is currently unknown. OBJECTIVES: To evaluate the immediate/delayed pruritus responses and the pruritic behaviours observed in the IL-31-induced pruritic model in healthy dogs after repeated IL-31 injections. ANIMALS: Fifteen healthy laboratory beagles. METHODS: All dogs were video-recorded for 270 min after two intravenous recombinant IL-31 injections (1.75 µg/kg) and vehicle (phosphate-buffered saline, control) injections, respectively; interventions were randomised and performed with a 2 week wash-out period. Two blinded investigators reviewed the pruritic behaviours of all video recordings. RESULTS: Both canine IL-31 (IL-31_01, IL-31_02) injections significantly increased pruritic seconds and categorical minutes ('YES'/'NO' behaviour per discrete 1 min interval) in healthy dogs compared with both vehicle groups (Vehicle_01, Vehicle_02). The second intravenous canine IL-31 (IL-31_02) administered 14 days after the first IL-31 injection induced a significant increase in pruritic seconds (p = 0.021) and not pruritic categorical minutes (p = 0.231). An increase in pruritic seconds was observed in both IL-31 groups in the first 30 min post-administration, while there was no significant difference between IL-31 and vehicle groups. CONCLUSIONS AND CLINICAL RELEVANCE: In conclusion, intravenous IL-31 reproducibly induces itch responses in dogs. Future evaluations of the canine IL-31 pruritic model should assess total pruritic behaviours in seconds rather than using a biased 'YES/NO' behaviour per 1 min scoring system.
Assuntos
Doenças do Cão , Interleucinas , Prurido , Animais , Cães , Prurido/veterinária , Prurido/induzido quimicamente , Doenças do Cão/induzido quimicamente , Interleucinas/administração & dosagem , Masculino , Feminino , Comportamento Animal/efeitos dos fármacos , Modelos Animais de Doenças , Injeções Intravenosas/veterináriaRESUMO
BACKGROUND: There have been no comparative bioavailability studies between the microemulsified ciclosporin formulation, approved for the treatment of canine atopic dermatitis (cAD), and the generic modified formulation of ciclosporin for humans. OBJECTIVES: To compare whole blood ciclosporin concentrations of oral generic modified ciclosporin (Treatment A; Teva Pharmaceuticals) and ciclosporin brand Atopica (Treatment B; Elanco Animal Health) in healthy dogs at 1 and 1.5 h following a single oral administration. METHODS: Whole blood concentrations were evaluated at 1 and 1.5 h post-oral administration of treatments A and B in a randomised, blinded, cross-over study with an 8-day wash-out, after a single administration at 4.4-5.3 mg/kg/day in eight healthy, male-castrated research beagle dogs. Ciclosporin blood concentrations were measured through the Auburn University Clinical Pharmacology Laboratory. RESULTS: Ciclosporin blood concentrations were below the detection limit before the start of treatment for both groups. Blood ciclosporin concentrations for Treatment A (median 1192 ng/ml) were significantly higher at 1 h post-oral administration than those for Treatment B (median 499 ng/ml; p = 0.001). However, no significant differences (p = 0.75) in ciclosporin values were observed at 1.5 h post-administration between treatments A (median 945 ng/ml) and B (median 809 ng/ml). CONCLUSIONS AND CLINICAL RELEVANCE: Generic modified ciclosporin achieved higher blood concentrations at 1 h post-administration than Atopica after a single oral administration in healthy dogs; no difference was noted at 1.5 h. Further clinical studies using generic modified ciclosporin in client-owned dogs affected with cAD are advocated to confirm its therapeutic efficacy.
Assuntos
Dermatite Atópica , Doenças do Cão , Drogas Veterinárias , Animais , Cães , Masculino , Administração Oral , Estudos Cross-Over , Ciclosporina/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/veterinária , Doenças do Cão/tratamento farmacológico , Drogas Veterinárias/uso terapêuticoRESUMO
In this report, we provide a case of self-limiting canine acute febrile sterile neutrophilic dermatosis in which the clinical signs featured typical target skin lesions with strong upregulation of T-helper 1 markers and interleukin-8, a potent neutrophil chemoattractant. Further, large case series are needed to characterize canine sterile neutrophilic dermatosis.
Dans cet article, nous présentons un cas de dermatose neutrophilique fébrile stérile aiguë canine spontanément résolutive dans laquelle les signes cliniques comportaient des lésions cutanées cibles typiques avec une forte régulation à la hausse des marqueurs T-helper 1 et de l'interleukine-8, un puissant chimioattractant des neutrophiles. D'autres grandes séries de cas sont nécessaires pour caractériser la dermatose neutrophile stérile canine.
En este artículo exponemos un caso de dermatosis neutrofílica estéril febril aguda canina autolimitante en la que los signos clínicos fueron lesiones cutáneas típicas en forma de diana con una intensa elevación de los marcadores T-helper 1 y de interleucina-8, un potente quimiotáctico de neutrófilos. Se necesitan series de casos más grandes para caracterizar la dermatosis neutrofílica estéril canina.
Neste relato, nós apresentamos um caso de dermatose neutrofílica estéril canina aguda febril em que os sinais clínicos típicos foram lesões cutâneas em alvo com forte ativação de marcadores T-helper 1 e interleucina-8, um potente quimioatrativo de neutrófilos. São necessários mais estudos com uma grande série de casos para caracterizar a dermatose neutrofílica estéril canina.
Assuntos
Dermatite , Doenças do Cão , Dermatopatias , Síndrome de Sweet , Cães , Animais , Regulação para Cima , Interleucina-8 , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/veterinária , Dermatopatias/patologia , Dermatopatias/veterinária , Dermatite/diagnóstico , Dermatite/veterinária , Neutrófilos/patologia , Doenças do Cão/diagnósticoRESUMO
BACKGROUND: Glycerinated allergen extracts contain 50% glycerin, an excellent preservative. While glycerin is a recognised irritant in humans, the utility of glycerinated extracts for intradermal testing has not been validated in dogs. HYPOTHESIS/OBJECTIVE: To determine and compare the effects of glycerin on immediate cutaneous reactions to intradermal injections of histamine and saline in healthy dogs. ANIMALS: Eight healthy laboratory beagles. MATERIALS AND METHODS: The study was designed as a randomised, blinded study. Intradermal injections of histamine (positive control) and saline (negative control) in aqueous and glycerinated (50%) forms were performed on the right thorax. Global wheal scores (GWS) at 20 min were evaluated by two independent investigators blinded to the interventions. RESULTS: There were no wheal and flare reactions observed after the intradermal injections of phenolated saline. By contrast, 50% glycerosaline injections induced erythema and induration in all dogs. Global wheal scores were significantly higher in aqueous histamine (Friedman test, p < 0.0001) and 50% glycerinated histamine (Friedman test, p = 0.0084) compared to phenolated saline controls. Interestingly, only aqueous histamine (Friedman test, p = 0.01) had significantly higher GWS than 50% glycerosaline injections, while no significant difference in GWS between 50% glycerinated histamine and 50% glycerosaline groups was observed (Friedman test, p = 0.59). CONCLUSION AND CLINICAL RELEVANCE: This study demonstrates that intradermal injection of 50% glycerosaline induces erythema and induration skin reactions in healthy dogs that can mimic positive reactions to allergenic extracts. Further dilutions of glycerinated positive and negative control solutions need to be optimised for intradermal testing in dogs.
Assuntos
Doenças do Cão , Glicerol , Animais , Cães , Alérgenos , Eritema/veterinária , Glicerol/efeitos adversos , Histamina , Injeções Intradérmicas/veterinária , Testes Intradérmicos/veterinária , FosfatosRESUMO
BACKGROUND: Previous evaluations of cytokine and chemokine gene expressions [messenger (m)RNA] in the skin of allergic cats were mostly unsuccessful in detecting the T-helper 2 (Th2) pathway, which is associated with the major effector cytokines interleukin (IL)-4, IL-5 and IL-13. HYPOTHESIS/OBJECTIVE: To evaluate differences in the mRNA expression in eosinophilic plaques of cats diagnosed with feline atopic skin syndrome (FASS) compared to healthy controls. ANIMALS: Four client-owned cats with FASS with eosinophilic plaques and five healthy control cats. MATERIALS AND METHODS: Gene expressions (mRNA) of 14 cytokines and chemokines from eosinophilic plaque skin of cats with FASS and site-matched skin samples from healthy controls were analysed using quantitative reverse-transcription PCR analysis. RESULTS: Eosinophilic plaques were characterized by upregulation of Th2 cytokines IL-4 (p ≤ 0.01), IL-5 (p ≤ 0.01) and IL-13 (p ≤ 0.01) and Th2-attracting chemokine CCL17 (p ≤ 0.05). Moreover, there was higher expression of S100 calcium-binding protein A 8 (p ≤ 0.01) as well as C-X-C Motif chemokine ligand 10 (CXCL10; p ≤ 0.01), IL-10 (p ≤ 0.05) and the Th17 cytokine IL-17A (p ≤ 0.01) in lesional skin compared to healthy samples. There was no difference in gene expressions of IL-12A, IL-31, IL-33, thymic stromal lymphopoietin (TSLP), tumour necrosis factor-α (TNF-α) or CCL5. CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrate that eosinophilic plaques feature dominant Th2 and IL-17A inflammatory responses in the skin. Further larger-sample transcriptome studies are needed to advance our understanding of the pathogenesis of different skin lesions in FASS.
Assuntos
Doenças do Gato , Dermatite Atópica , Dermatopatias , Gatos , Animais , Citocinas/genética , Citocinas/metabolismo , Interleucina-17 , Dermatite Atópica/genética , Dermatite Atópica/veterinária , Interleucina-13/genética , Interleucina-5/genética , Dermatopatias/veterinária , Perfilação da Expressão Gênica/veterinária , RNA Mensageiro/metabolismoRESUMO
BACKGROUND: Dilute sodium hypochlorite (bleach) baths at 0.005% concentration twice weekly have been shown to markedly reduce the severity of atopic dermatitis in children, yet no tolerability and efficacy data are available for this treatment in dogs. OBJECTIVES: To determine the local tolerability and the longitudinal effect on the density of Staphylococcus pseudintermedius of repeated diluted bleach baths on healthy dog skin. ANIMALS: Four healthy hound cross-bred dogs. METHODS: Bleach baths (0.005%; twice weekly for 15 min) were applied to four healthy hound cross-bred dogs over four weeks (eight baths). Local tolerability was assessed for axillae, abdomen and legs by an investigator before, immediately after and 24 h after each bath. The longitudinal effect on density of S. pseudintermedius from axillae and groin was analysed through quantitative PCR before treatment [at Day (D)-7 and -3], during treatment on D4, D11 and D25, and on D30. RESULTS: There was no erythema or scaling after the baths in any dog. Copy numbers of S. pseudintermedius in axillae, groin and both (axillae and groin together) were not significantly different at any time point during the study. CONCLUSIONS AND CLINICAL RELEVANCE: Repeated 0.005% hypochlorite bleach baths over four weeks were safe and well-tolerated in healthy dogs without significant changes in the density of S. pseudintermedius.
Assuntos
Anti-Infecciosos , Hipoclorito de Sódio , Cães , Animais , Hipoclorito de Sódio/farmacologia , Ácido Hipocloroso , Banhos/veterinária , PeleRESUMO
BACKGROUND: A new canine subgroup defined as 'old-dog' or 'hyperkeratotic' erythema multiforme (HKEM) with marked hyperkeratosis and parakeratosis has been proposed without any detailed description of larger case series. OBJECTIVES: We report herein the signalment, clinical signs, treatment outcome, and histopathological and immunological findings in 17 dogs with HKEM. ANIMALS: Inclusion criteria were the presence of (i) scaly skin lesions with or without crusting; and (ii) microscopic lesions typical of EM (i.e. a panepidermal cytotoxic lymphocytic dermatitis with or without basal keratinocyte apoptosis); and (iii) microscopic ortho- and/or parakeratotic hyperkeratosis affecting the interfollicular epidermis. MATERIALS AND METHODS: Clinical questionnaires and skin biopsies were reviewed. Polymerase chain reactions for epidermotropic viruses and direct immunofluorescence were performed. RESULTS: Various breeds were affected with an over-representation of males in their mid-to-late adulthood (median age 9 years). Generalised skin lesions included multifocal-to-coalescing, linear and annular macules and plaques with erythema and adherent firm crusting. Microscopic lesions were specific for EM and featured prominent superficial epidermal apoptosis with lymphocytic satellitosis and parakeratosis. No drug triggers were identified. Polymerase chain reactions for canine herpesvirus polymerase gene, canine parvovirus and canine distemper virus were negative in all HKEM and canine erosive EM (15 dogs) biopsies. Lesions failed to respond to oral and/or topical antimicrobials. Complete remission of signs was achieved in 9 of 17 dogs (53%) using immunosuppressive regimens. CONCLUSIONS AND CLINICAL RELEVANCE: Hyperkeratotic erythema multiforme (HKEM) is a chronic, persistent and clinically distinctive erythema multiforme (EM) variant that differs from 'classic' vesiculobullous erosive-to-ulcerative EM in dogs.
Assuntos
Doenças do Cão , Eritema Multiforme , Paraceratose , Masculino , Cães , Animais , Paraceratose/patologia , Paraceratose/veterinária , Doenças do Cão/diagnóstico , Eritema Multiforme/tratamento farmacológico , Eritema Multiforme/veterinária , Eritema Multiforme/diagnóstico , Pele/patologia , Epiderme/patologiaRESUMO
BACKGROUND: Oral mycophenolate mofetil (MMF) currently is considered a low-risk steroid-sparing therapeutic option for the management of canine pemphigus foliaceus (PF). OBJECTIVES: This retrospective study evaluates the therapeutic outcomes of dogs with PF treated with the combination of oral MMF and glucocorticoid (GC). Clinical outcomes and adverse side effects are reported. ANIMALS: Eleven dogs diagnosed with PF. MATERIALS AND METHODS: Retrospective review of medical records from dogs presented with PF to the dermatology service of a veterinary teaching hospital between 2015 and 2020. RESULTS: Eleven dogs were identified which had received concurrent GCs and MMF. The MMF dose range was 19.8-45 mg/kg/day. Only two dogs (two of 11) treated with a mean MMF dosage of 39 mg/kg/day along with oral prednisone or dexamethasone achieved complete remission (CR). Partial remission (PR) was achieved in four of 11 dogs who received either prednisone, prednisolone or dexamethasone along with MMF (mean dosage 26 mg/kg/day). Four dogs (four of 11) showed poor response to MMF given at 28.5 mg/kg/day along with prednisone or dexamethasone. In one dog (one of 11) MMF was discontinued due to severe GI upset; transient vomiting and diarrhea was observed in four of 11 dogs. The median duration of MMF therapy in conjunction with GC for all groups was 70.5 days. Tapering of oral GCs while continuing MMF administration at the same dosage and frequency led to recurrence of lesions in all PF patients. CONCLUSION: Oral MMF combined with GC achieved CR in two of 11 PF dogs included in this study. Further research of MMF efficacy in PF may need to be performed.
Assuntos
Doenças do Cão , Pênfigo , Animais , Doenças do Cão/tratamento farmacológico , Cães , Quimioterapia Combinada/veterinária , Hospitais Veterinários , Hospitais de Ensino , Imunossupressores/uso terapêutico , Ácido Micofenólico/uso terapêutico , Pênfigo/tratamento farmacológico , Pênfigo/veterinária , Estudos Retrospectivos , Esteroides/uso terapêutico , Resultado do TratamentoRESUMO
BACKGROUND: Feline atopic skin syndrome (FASS) is a pruritic and inflammatory skin disease commonly encountered in cats. Three previous reports evaluated cytokine immune activation in cats diagnosed with feline allergic dermatitis. However, no significant upregulations were observed in allergic cats compared to healthy controls. HYPOTHESIS/OBJECTIVE: To evaluate differences in the serum cytokine profile of cats diagnosed with FASS compared to healthy cats, and correlate serum markers with the extent of FASS skin disease using clinical scoring systems. ANIMALS: Thirteen client-owned FASS cats and 12 healthy control cats. METHODS AND MATERIALS: Thirteen cytokine and chemokines from the serum of FASS cats and healthy controls were analysed using a commercially available feline-specific multiplex assay. RESULTS: Patients with FASS had a significant increase in serum concentrations of interferon-gamma (IFN-γ), interleukin (IL)-2, IL-13 and IL-18. In addition, cytokine/chemokines involved in inflammation and chemotaxis [IL-8, C-C Motif Chemokine Ligand (CCL)5, CCL2 and CXCL12], as well as growth factors, stem cell factor and Fms-related tyrosine kinase 3 ligand (Flt3L), also were significantly elevated. A significant positive correlation (r = 0.64) between the serum levels of Flt3L and Scoring Feline Allergic Dermatitis (SCORFAD) score was observed. CONCLUSIONS: These results demonstrate the activation of a broad array of immune secretory cytokines in the serum of cats with FASS, which are largely associated with a mixed Th1 and Th2 inflammatory response along with specific growth factors. Further larger-sample studies are needed to assess the modulation of serum biomarkers in FASS by pharmacological/therapeutic interventions.
Assuntos
Doenças do Gato , Dermatite Atópica , Hipersensibilidade , Alérgenos , Animais , Gatos , Citocinas , Dermatite Atópica/veterinária , Hipersensibilidade/veterinária , PeleRESUMO
BACKGROUND: There are no liquid oral glucocorticoids labelled for management of pruritus and clinical lesions of feline hypersensitivity dermatitis (feline HD). HYPOTHESIS: First, to demonstrate that dexamethasone sodium phosphate (DexSP, DexajectSP, Henry Schein; Dublin, OH, USA; 4 mg/mL), an intravenous glucocorticoid, can be absorbed by healthy cats when administered orally. Second, to demonstrate the efficacy of orally administered DexSP for reducing pruritus and clinical lesions in patients with feline HD. ANIMALS: Seven healthy and 12 client-owned cats with HD. METHODS AND MATERIALS: Healthy cats were administered a single dose of 0.2 mg/kg DexSP p.o. and serum concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Feline HD patients were assessed with SCORing Feline Allergic Dermatitis (SCORFAD) and pruritus Visual Analog Scale (pVAS) at Visit 1 (V1) and after 20-31 days of receiving 0.2 mg/kg/day DexSP p.o. (V2). Complete blood cell counts, serum chemistry profile, and urinalysis were performed in 50% of feline HD patients at both visits. RESULTS: Healthy cats had detectable serum concentrations of DexSP following oral administration; concentrations ranged from 0.7 to 92.3 ng/mL. Feline HD patients showed significant decreases in SCORFAD and pVAS scores from V1 to V2. CONCLUSIONS: DexSP was absorbed when administered orally to healthy cats and 0.2 mg/kg/day DexSP is an efficacious dose to rapidly improve the pruritus and clinical lesions associated with feline HD.
Assuntos
Doenças do Gato , Dermatite Atópica , Hipersensibilidade , Administração Oral , Animais , Doenças do Gato/tratamento farmacológico , Gatos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/veterinária , Dexametasona/análogos & derivados , Hipersensibilidade/veterinária , Prurido/induzido quimicamente , Prurido/tratamento farmacológico , Prurido/veterináriaRESUMO
BACKGROUND: Feline diseases of possible allergic origin with similar clinical phenotypes can have a varied underlying pathogenesis. Clinical phenotype, precise aetiology and underlying immunopathogenesis all need to be considered if advances in this neglected area of dermatology are to be made. OBJECTIVES: To document the status of research into the immunopathogenesis of the diseases that fall within the spectrum of the feline atopic syndrome (FAS ), to summarize the conclusions, identify the limitations and recommend future research directions. METHODS AND MATERIALS: A search of the literature was undertaken. The strengths and validity of the data and the contributions to our current understanding of the immunopathogenesis were analysed. Skin diseases of presumed allergic aetiology and asthma were assessed separately, as was the role of antibodies, cells and cytokines in each. RESULTS: The research varied in its quality and its impact often was limited by a failure to employ strict criteria in case selection. This reflected the difficulties of skin reaction patterns associated with a number of inciting causes. Research into feline asthma was handicapped by the difficulties of investigating clinical material, and much of the useful information was derived from experimental models. CONCLUSIONS AND CLINICAL IMPORTANCE: The evidence reviewed was supportive of a role for immunoglobulin (Ig)E in the pathogenesis of both feline atopic skin syndrome (FASS) and asthma, albeit not strongly so. The inflammation noted in both FASS and asthma is accompanied by eosinophils and lymphocytes, and these findings, together with the cytokine expression, are suggestive in some (not all) cats of T-helper type 2 immune dysregulation.
Assuntos
Doenças do Gato , Dermatite Atópica , Hipersensibilidade Imediata , Alérgenos , Animais , Asma/imunologia , Asma/fisiopatologia , Asma/veterinária , Doenças do Gato/imunologia , Doenças do Gato/fisiopatologia , Gatos , Dermatite Atópica/imunologia , Dermatite Atópica/fisiopatologia , Dermatite Atópica/veterinária , Hipersensibilidade/veterinária , Hipersensibilidade Imediata/veterinária , Doenças do Sistema Imunitário/fisiopatologia , Doenças do Sistema Imunitário/veterinária , Imunoglobulina E/imunologia , SíndromeRESUMO
BACKGROUND: Feline allergic diseases present as challenging problems for clinicians, not least because of the number of reaction patterns of the feline skin, none of which are specific for allergy. Furthermore, there is some controversy over the nomenclature that should be used in their description. OBJECTIVES: To review the literature, assess the status of knowledge of the topic and the extent to which these diseases could be categorized as atopic in nature, and make recommendations concerning nomenclature. METHODS: Atopic diseases in humans and cats were researched. A comparison then was made of the essential features in the two species. RESULTS: There were sufficient similarities between human atopic diseases and the manifestations of feline diseases of presumed allergic aetiology to justify the use of "atopic" to describe some of the feline conditions affecting the skin, respiratory and gastrointestinal tract. However, none of the allergic skin diseases showed features consistent with atopic dermatitis as described in man and the dog. CONCLUSIONS AND CLINICAL IMPORTANCE: The term "Feline Atopic Syndrome" (FAS) is proposed to encompass allergic diseases of the skin, gastrointestinal tract and respiratory tract, and "Feline atopic skin syndrome" (FASS) proposed to describe allergic skin disease associated with environmental allergies. We are not aware of any adverse food reactions in cats that are attributable to causes other than immunological reactions against the food itself. We therefore propose an aetiological definition of "Food Allergy" (FA) to describe such cases.
Assuntos
Doenças do Gato , Dermatite Atópica , Terminologia como Assunto , Alérgenos , Animais , Doenças do Gato/classificação , Doenças do Gato/imunologia , Doenças do Gato/patologia , Gatos , Dermatite Atópica/classificação , Dermatite Atópica/imunologia , Dermatite Atópica/patologia , Dermatite Atópica/veterinária , Cães , Hipersensibilidade Alimentar/veterinária , Humanos , Pele/patologiaRESUMO
BACKGROUND: Chloroquine (CQ) is a prototypical systemic and intradermal pruritogen for histamine-independent (nonhistaminergic) itch in mice and humans. The predictive validity of this model is poorly documented in dogs. HYPOTHESIS/OBJECTIVE: To determine pruritogenic and inflammatory effects of systemic and i.d. CQ injections in healthy dogs. ANIMALS: Ten healthy purpose-bred laboratory beagles. METHODS AND MATERIALS: All dogs were randomized to receive i.d. (200 and 400 µg/site), intravenous (2 mg/kg) and subcutaneous (3 mg/kg) CQ injections. Dogs were video-recorded for 30 min after i.d. injections and for 300 min after i.v. and s.c. injections. Buffered saline injections served as controls for each route. Global wheal scores were evaluated at 30 min post-i.d. injection by a blinded investigator. RESULTS: All dogs showed wheal and erythema at the CQ i.d. injection sites; global wheal scores of each CQ concentration were significantly increased compared to placebo (P ≤ 0.05). Blinded evaluation revealed no significant increase in generalized pruritic behaviour (pruritic seconds) after i.v. or s.c. administration of CQ. Intradermal injections induced mild localized acute pruritic behaviours at the site of injections at 200 µg (P = 0.06) and 400 µg (P = 0.27) CQ in dogs. CONCLUSION AND CLINICAL SIGNIFICANCE: To the best of the authors' knowledge, this is the first report which shows that i.d. CQ injections may induce acute inflammation in healthy dogs. By contrast to the systemic CQ-induced pruritus reported previously in healthy mice and dogs, no significant pruritic behaviours were observed after CQ injection, regardless of the route of administration.
Assuntos
Cloroquina/efeitos adversos , Eritema/veterinária , Prurido/veterinária , Pele/efeitos dos fármacos , Administração Intravenosa , Animais , Cloroquina/administração & dosagem , Estudos Cross-Over , Modelos Animais de Doenças , Cães , Eritema/induzido quimicamente , Inflamação/induzido quimicamente , Inflamação/veterinária , Injeções Subcutâneas , Masculino , Prurido/induzido quimicamente , Distribuição AleatóriaRESUMO
BACKGROUND: Currently, there is insufficient evidence to confirm oral diphenhydramine (DPH) efficacy to prevent mast cell degranulation and histamine release in dogs. HYPOTHESIS/OBJECTIVE: To determine and compare the effects oral of DPH and cetirizine on the immediate- and late-phase cutaneous allergic reactions in healthy dogs. ANIMALS: Twelve healthy laboratory beagle dogs. METHODS AND MATERIALS: The study was designed as a randomized, double-blinded crossover study in which each dog served as its own control; twice-daily oral DPH (2.2 mg/kg) or cetirizine (2 mg/kg) were given for six days with a two week washout period. Intradermal injections of histamine, compound 48/80 (positive control) and saline (negative control) were performed on the right thorax 10 days before drug administration (baseline), during oral antihistamine administration on Day 6 and 10 days after last medication dosage. Global wheal scores (GWS) at 20 min and late-phase reactions (LPR) at 6 h post-injection were evaluated by an investigator blinded to the drug and the interventions. RESULTS: Treatment with cetirizine significantly reduced histamine and compound 48/80 GWS and LPR compared to baseline; there was no significant difference for DPH. In all dogs, oral DPH and cetirizine reached plasma concentrations considered therapeutic in people. No adverse effect or behavioural changes were observed during the study. CONCLUSION AND CLINICAL SIGNIFICANCE: In conclusion, oral cetirizine was effective in preventing cutaneous allergic reactions without any obvious adverse effects in dogs. Oral DPH failed to show an inhibitory effect despite attaining plasma drug concentrations that are considered effective in people.
Assuntos
Cetirizina/uso terapêutico , Difenidramina/uso terapêutico , Doenças do Cão/tratamento farmacológico , Hipersensibilidade/tratamento farmacológico , Hipersensibilidade/veterinária , Pele/efeitos dos fármacos , Animais , Estudos Cross-Over , Cães , Método Duplo-Cego , Histamina/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Masculino , Pele/patologia , Testes Cutâneos , p-Metoxi-N-metilfenetilamina/administração & dosagemRESUMO
BACKGROUND: Scratching behaviours associated with intradermal (i.d.) injection of pruritogens such as histamine and compound 48/80 into the skin of mice and humans is the commonly used model to advance itch research and drug development. The predictive validity of this model is poorly documented in dogs. OBJECTIVES: To evaluate the dose-dependent effects of pruritogenic substances, each with a different mechanism of action, in healthy dogs. ANIMALS: Ten healthy laboratory beagles. METHODS AND MATERIALS: All dogs were video-recorded for 30 min post-injection (mpi) of i.d. goat anti-canine IgE (4 and 25 µg/site), histamine and compound 48/80 (50, 100, 200, 400 µg/site); two buffered saline injections served as controls. Two blinded investigators reviewed the pruritic behaviours of all video recordings. Global wheal scores were evaluated at 30 min by a blinded investigator. RESULTS: All dogs showed wheal and erythema at the pruritogen injection site; global wheal scores at 30 min of each substance significantly increased at all concentrations compared to control (P ≤ 0.05). A blinded evaluation revealed that all pruritogens induced mild acute pruritic behaviours at the site of injection. There was no injection site pain seen in any dog. Compared to controls, injections of pruritogens did not significantly affect the pruritic seconds or occurrence of pruritic episodes for any of the substances. CONCLUSIONS AND CLINICAL SIGNIFICANCE: These preliminary results suggest that i.d. injections of the studied pruritogens can induce cutaneous wheal and flare response in healthy dogs; but inconsistencies occur in the induction of itch, even with the different concentrations of pruritogens.
Assuntos
Anticorpos Anti-Idiotípicos/administração & dosagem , Eritema/veterinária , Histamina/administração & dosagem , Prurido/veterinária , p-Metoxi-N-metilfenetilamina/administração & dosagem , Animais , Anticorpos Anti-Idiotípicos/efeitos adversos , Cães , Relação Dose-Resposta a Droga , Histamina/efeitos adversos , Injeções Intradérmicas , Masculino , Prurido/induzido quimicamente , Pele/efeitos dos fármacos , p-Metoxi-N-metilfenetilamina/efeitos adversosRESUMO
BACKGROUND: Cutaneous mastocytosis (CM) is a rare disease of dogs characterized by rash, pruritus and proliferation of mast cells in the skin. Oral H1 antihistamines are recommended as the treatment to control pruritus. HYPOTHESIS/OBJECTIVE: To describe the effective treatment of pruritus associated with CM with lokivetmab in one dog. ANIMAL: A 4-year-old, spayed female cross-bred dog presented with severely pruritic, erythematous to pigmented macules and papules involving the ventral abdomen, interdigital skin, perivulval area and both pinnae; the pruritus had been unresponsive to treatment with antihistamines, prednisone and ciclosporin. METHODS AND MATERIALS: Complete blood count and serum biochemistry, abdominal ultrasound, blood smear and skin cytological evaluation, PCR, histopathological and immunohistochemical examination of skin biopsies. RESULTS: Skin cytological evaluation revealed high numbers of uniform, heavily granulated mast cells; histopathological findings showed focal dermal proliferations of well-differentiated, uniform mast cells consistent with a low-grade mast cell tumour (MCT). Clinical staging revealed that the disease was confined to the skin. Mutations of c-kit exon 8 and 11 were not detected. Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin lesions improved but did not resolve. CONCLUSION AND CLINICAL IMPORTANCE: Lokivetmab treatment was effective in resolving and maintaining pruritus remission in this dog with widespread cutaneous mast cell disease. Whether CM in dogs represent a separate entity that should be distinguished from a low-grade MCT requires further investigation.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Mastocitose Cutânea/veterinária , Prurido/veterinária , Animais , Anticorpos Monoclonais/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Doenças do Cão/diagnóstico , Doenças do Cão/patologia , Cães , Feminino , Injeções Subcutâneas/veterinária , Mastocitose Cutânea/complicações , Mastocitose Cutânea/tratamento farmacológico , Mastocitose Cutânea/patologia , Prurido/tratamento farmacológico , Prurido/etiologia , Prurido/patologia , Pele/patologiaRESUMO
BACKGROUND: Immune-modulating drugs show limited therapeutic efficacy in canine exfoliative cutaneous lupus erythematosus (ECLE); over half of ECLE dogs are eventually euthanized for their lack of response to therapy. OBJECTIVE: To describe a case of generalized ECLE in a dog in which mycophenolate mofetil (MMF) treatment achieved complete remission. ANIMAL: A 3-year-old, male castrated German shorthaired pointer was presented with a three months history of generalized scaling, erythematous macules and plaques, follicular casts and hypotrichosis affecting the head, trunk, ventrum and medial aspects of all limbs. The dog exhibited lameness and stiff gait. METHODS AND MATERIALS: Complete blood count, serum chemistry profile, urinalysis, serum antinuclear antibody test, histopathological examination and RT-qPCR of skin biopsies. RESULTS: Histologically, skin biopsy specimens revealed lymphocyte-rich interface dermatitis, infundibular interface mural folliculitis and periglandular lymphocytic infiltrate. The absence of systemic signs and unremarkable laboratory tests excluded concurrent systemic lupus erythematosus. Treatment of ECLE was initiated with oral MMF (22 mg/kg, twice daily). Within three weeks of starting MMF therapy, a marked improvement in lameness and a moderate decrease in erythema and scaling was observed. After four months, erythema, scaling and follicular casts had completely resolved, and at the time of writing the dog's ECLE remains in complete remission with twice daily MMF (10 mg/kg). The lesional skin transcriptome revealed predominant T helper 1 (Th1) lymphocytic inflammatory response with strong upregulation of interferon pathway. CONCLUSIONS AND CLINICAL IMPORTANCE: To the best of the authors' knowledge, this is the first reported case of successful treatment of ECLE with MMF as a single-agent therapy.
Assuntos
Doenças do Cão/tratamento farmacológico , Lúpus Eritematoso Cutâneo/veterinária , Ácido Micofenólico/uso terapêutico , Pele/efeitos dos fármacos , Animais , Quimiocinas/genética , Citocinas/genética , Doenças do Cão/patologia , Cães , Lúpus Eritematoso Cutâneo/tratamento farmacológico , Masculino , Indução de Remissão , Pele/patologia , Resultado do TratamentoRESUMO
BACKGROUND: Oclacitinib is a Janus kinase inhibitor used to control pruritus and skin lesions in canine allergic skin disease; its effect on canine T cells is not well-characterized. HYPOTHESIS/OBJECTIVES: To evaluate the impact of oclacitinib on cultured T cells using peripheral blood mononuclear cells from dogs. ANIMALS: Six bluetick coonhounds. METHODS AND MATERIALS: Lymphocyte-enriched cells were incubated with or without the T-cell mitogen concanavalin A (Con A), oclacitinib (0.5, 1 or 10 µM), ciclosporin (200 ng/mL), Con A + oclacitinib 1 µM and Con A + ciclosporin. We assessed both T-cell proliferation and the secretion of cytokines. RESULTS: Ciclosporin and oclacitinib both inhibited the spontaneous proliferation of T cells; this effect was significant only after incubation with oclacitinib at 10 µM. At this concentration, oclacitinib significantly reduced the spontaneous secretion of clonal activator cytokines [interleukin (IL)-2, IL-15], pro-inflammatory cytokines (interferon-gamma (IFN-γ), IL-18) and the regulatory cytokine IL-10; tumour necrosis factor alpha (TNF-α) and IL-6 cytokine production was mildly inhibited. After Con A stimulation, only T cells co-treated with ciclosporin achieved a significant proliferation inhibition and reduction of IL-2, IL-10, IL-15, IL-18, IFN-γ and TNF-α. Surprisingly, oclacitinib at 1 µM (337 ng/mL, corresponding to the oral dosage of 0.4-0.6 mg/kg) did not significantly affect Con A-stimulated T-cell proliferation nor cytokine production (IL-2, IL-10, IL-15, IL-18, IFN-γ and TNF-α). CONCLUSIONS: Although a limited number of dogs were investigated, these preliminary results suggest that oclacitinib appears to have immunosuppressive properties, but only at dosages above those used to treat allergic pruritus in dogs.
Assuntos
Citocinas/metabolismo , Fatores Imunológicos/farmacologia , Pirimidinas/farmacologia , Sulfonamidas/farmacologia , Linfócitos T/efeitos dos fármacos , Animais , Ciclosporina/farmacologia , Cães , Feminino , Interferon gama/metabolismo , Interleucina-10/metabolismo , Interleucina-15/metabolismo , Interleucina-18/metabolismo , Interleucina-2/metabolismo , Ativação Linfocitária/efeitos dos fármacos , Masculino , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Since the first description of discoid lupus erythematosus (LE) in two dogs in 1979, the spectrum of canine cutaneous lupus erythematosus (CLE) variants has expanded markedly.In this review, we first propose an adaptation of the Gilliam-Sontheimer classification of CLE for dogs. We then review the signalment, clinical signs, laboratory and histopathology and treatment outcome of the currently recognized variants of canine CLE, which are vesicular CLE, exfoliative CLE, mucocutaneous LE and facial or generalized discoid LE. We end with a short description of the rare cutaneous manifestations of systemic LE in dogs.Canine CLE variants are heterogeneous, some of them mirror their human counterparts while others appear-thus far-unique to the dog. As most CLE subtypes seem to have a good prognosis after diagnosis, veterinarians are encouraged to become familiar with the spectrum of often-characteristic and unique clinical signs that would permit an early diagnosis and the rapid implementation of an effective treatment.